Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets Hard-to-Treat cancers with RAS mutations

NCT ID NCT07678593

Not yet recruiting Disease control Sponsor: Genfleet Therapeutics (Shanghai) Inc. Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. The trial involves about 222 participants and is conducted in two phases: first to check safety, then to measure tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GFH276 (oral drug) combined with cetuximab or chemotherapy (nab-paclitaxel, gemcitabine, fluorouracil, leucovorin)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors or pancreatic cancer that have a RAS mutation.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not work as hoped or could cause significant side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CANCER PANCREATIC DUCTAL ADENOCARCINOMA RAS MUTATION

Contacts and locations

Locations

  • Concord Cancer Centre, Concord Repatriation General Hospital, Sydney Local Health District

    Concord, New South Wales, 2139, Australia

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

  • Macquarie University / Clinical Trials Unit

    North Ryde, New South Wales, 2109, Australia

  • Monash Health (Monash Medical Centre)

    Clayton, Victoria, 3168, Australia

  • Northern Health

    Epping, Victoria, 3076, Australia

  • PASO Medical

    Frankston, Victoria, 3199, Australia

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • Shandong First Medical University Affiliated Tumor Hospital

    Jinan, Shandong, 250117, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310016, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510120, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, 110001, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, 710061, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450052, China

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, 5011, Australia

  • The Third Affiliated Hospital (Cancer Hospital) of Harbin Medical University

    Harbin, Heilongjiang, 150081, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.